

Animesh D Pardanani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6742541/publications.pdf>

Version: 2024-02-01

354
papers

16,090
citations

20817

60
h-index

18130

120
g-index

354
all docs

354
docs citations

354
times ranked

8725
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. British Journal of Haematology, 2022, 196, 975-983. | 2.5 | 14 |
| 2 | Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35. | 4.1 | 18 |
| 3 | Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>) but not in <scp>MDS</scp>/<scp>MPNâ€RSâ€T</scp>. American Journal of Hematology, 4.1 2022, 97, . | 4.1 | 6 |
| 4 | Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience. American Journal of Hematology, 2022, 97, . | 4.1 | 7 |
| 5 | Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26. | 6.2 | 5 |
| 6 | <i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192. | 3.5 | 3 |
| 7 | Erythrocytosis associated with <i>EPAS1</i>, <i>HIF2A</i>, <i>EGLN1</i>, <i>PHD2</i>, <i>VHL</i>, <i>EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience. Haematologica, 2022, 107, 1201-1204. | 3.5 | 4 |
| 8 | Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. American Journal of Hematology, 2022, 97, 630-637. | 4.1 | 11 |
| 9 | Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American Journal of Hematology, 2022, 97, . | 4.1 | 10 |
| 10 | Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer Journal, 2022, 12, 44. | 6.2 | 9 |
| 11 | Mast cell sarcoma: 2 Mayo Clinic cases. American Journal of Hematology, 2022, 97, 1381-1383. | 4.1 | 5 |
| 12 | Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Research, 2022, 82, 749-763. | 0.9 | 20 |
| 13 | Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20â€mg twice daily or higher: A realâ€world experience. British Journal of Haematology, 2022, 198, . | 2.5 | 7 |
| 14 | A dynamic 3â€factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134. | 4.1 | 7 |
| 15 | The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€“ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9. | 2.7 | 8 |
| 16 | Young platelet millionaires with essential thrombocythemia. American Journal of Hematology, 2021, 96, E93-E95. | 4.1 | 11 |
| 17 | Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. American Journal of Hematology, 2021, 96, 508-525. | 4.1 | 104 |
| 18 | Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150. | 4.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49. | 6.2 | 28 |
| 20 | Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus <sc>HMA</sc>±venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111. | 4.1 | 7 |
| 21 | Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46. | 6.2 | 6 |
| 22 | CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54. | 6.2 | 5 |
| 23 | Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American Journal of Hematology, 2021, 96, E182-E184. | 4.1 | 11 |
| 24 | Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77. | 6.2 | 26 |
| 25 | JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. Leukemia, 2021, 35, 2166-2181. | 7.2 | 35 |
| 26 | Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789. | 4.1 | 46 |
| 27 | Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122. | 6.2 | 7 |
| 28 | Pregnancy in patients with myelofibrosis: Mayo's "Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137. | 2.5 | 2 |
| 29 | Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate- or high-risk myelofibrosis. British Journal of Haematology, 2021, 195, 244-248. | 2.5 | 37 |
| 30 | <i>De novo</i> isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416. | 2.5 | 9 |
| 31 | Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480. | 4.1 | 20 |
| 32 | A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American Journal of Hematology, 2021, 96, E464-E468. | 4.1 | 9 |
| 33 | High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. American Journal of Hematology, 2021, 96, 1647-1654. | 4.1 | 8 |
| 34 | <i>JAK2</i> wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood, 2021, 138, 2886-2889. | 1.4 | 12 |
| 35 | High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. Blood, 2021, 138, 1492-1492. | 1.4 | 0 |
| 36 | Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. <i>Blood</i> , 2021, 138, 238-238. | 1.4 | 2 |
| 38 | Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 3651-3651. | 1.4 | 1 |
| 39 | Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021, 138, 3657-3657. | 1.4 | 1 |
| 40 | Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021, 138, 3368-3368. | 1.4 | 1 |
| 41 | The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. <i>Blood</i> , 2021, 138, 3630-3630. | 1.4 | 0 |
| 42 | Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR-ABL1</i> like (<i>P</i> -hiladelphia chromosome like) <i>B</i> -acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E68-E72. | 4.1 | 4 |
| 43 | Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020, 34, 1407-1421. | 7.2 | 68 |
| 44 | Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151412. | 1.3 | 9 |
| 45 | Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521. | 4.1 | 83 |
| 46 | 81-Year-Old Man With Insomnia and Pruritus. <i>Mayo Clinic Proceedings</i> , 2020, 95, e59-e64. | 3.0 | 0 |
| 47 | A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68. | 6.2 | 8 |
| 48 | Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600. | 1.3 | 17 |
| 49 | Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. <i>American Journal of Hematology</i> , 2020, 95, 1224-1225. | 4.1 | 4 |
| 50 | A population-based study of chronic eosinophilic <i>leukemia</i> not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020, 95, E257. | 4.1 | 6 |
| 51 | Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020, 34, 2519-2524. | 7.2 | 25 |
| 52 | Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020, 189, 291-302. | 2.5 | 134 |
| 53 | Phenotypic correlates and prognostic outcomes of <i>TET2</i> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. <i>American Journal of Hematology</i> , 2020, 95, E86-E89. | 4.1 | 3 |
| 54 | Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. <i>American Journal of Hematology</i> , 2020, 95, E114-E117. | 4.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | <scp>WHO</scp> defined chronic eosinophilic leukemia, not otherwise specified (<scp>CEL</scp>,) Tj ETQq1 1 0.784314 rgBT /Overlo 95, E172-E174. | 4.1 | 26 |
| 56 | A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40. | 1.4 | 10 |
| 57 | Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1248-1269. | 4.9 | 21 |
| 58 | Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35. | 1.4 | 0 |
| 59 | Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36. | 1.4 | 0 |
| 60 | A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31. | 1.4 | 0 |
| 61 | Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20. | 1.4 | 0 |
| 62 | Phenotypic heterogeneity associated with germline <i>GATA2</i> haploinsufficiency: a comprehensive kindred study. Leukemia and Lymphoma, 2019, 60, 3282-3286. | 1.3 | 4 |
| 63 | Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550. | 3.0 | 6 |
| 64 | Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12. | 6.2 | 52 |
| 65 | Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234. | 4.1 | 9 |
| 66 | Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. Leukemia, 2019, 33, 2522-2553. | 7.2 | 1 |
| 67 | World Health Organization class-independent risk categorization in mastocytosis. Blood Cancer Journal, 2019, 9, 29. | 6.2 | 12 |
| 68 | 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610. | 3.0 | 103 |
| 69 | Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779. | 4.1 | 51 |
| 70 | A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11. | 6.2 | 9 |
| 71 | Essential Thrombocythemia. New England Journal of Medicine, 2019, 381, 2135-2144. | 27.0 | 106 |
| 72 | Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Mutations and prognosis in myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019, 60, 1112-1113. | 1.3 | 1 |
| 74 | Calculator of free point-of-care prognostication in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2019, 94, E99-E101. | 4.1 | 0 |
| 75 | Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. <i>Leukemia</i> , 2019, 33, 780-785. | 7.2 | 4 |
| 76 | The germline <i>JAK2</i> GGCC (46/1) haplotype and survival among 414 molecularly annotated patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2019, 94, 299-305. | 4.1 | 11 |
| 77 | 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019, 94, 286-290. | 4.1 | 10 |
| 78 | Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. <i>American Journal of Hematology</i> , 2019, 94, E1-E2. | 4.1 | 16 |
| 79 | Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019, 94, 5-9. | 4.1 | 7 |
| 80 | Spectrum of Abnormalities and Clonal Transformation in Germline <i>RUNX1</i> Familial Platelet Disorder and a Comparative Analysis with Somatic <i>RUNX1</i> Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 3003-3003. | 1.4 | 1 |
| 81 | Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019, 134, 558-558. | 1.4 | 19 |
| 82 | Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182. | 1.4 | 1 |
| 83 | Phenotypic Correlates and Prognostic Outcomes of <i>TET2</i> Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019, 134, 3005-3005. | 1.4 | 0 |
| 84 | Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 1697-1697. | 1.4 | 4 |
| 85 | Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863. | 1.4 | 1 |
| 86 | Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019, 134, 1710-1710. | 1.4 | 0 |
| 87 | Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E144-E146. | 4.1 | 2 |
| 88 | <i>U2AF1</i> mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. <i>Leukemia</i> , 2018, 32, 2274-2278. | 7.2 | 75 |
| 89 | <i>U2AF1</i> mutation variants in myelodysplastic syndromes and their clinical correlates. <i>American Journal of Hematology</i> , 2018, 93, E146-E148. | 4.1 | 15 |
| 90 | The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E164-E167. | 4.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018, 32, 1631-1642. | 7.2 | 213 |
| 92 | Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. <i>Leukemia</i> , 2018, 32, 1254-1258. | 7.2 | 42 |
| 93 | Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018, 32, 1200-1210. | 7.2 | 101 |
| 94 | Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18. | 6.2 | 19 |
| 95 | Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , 2018, 32, 1189-1199. | 7.2 | 102 |
| 96 | Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018, 93, 691-697. | 4.1 | 50 |
| 97 | Mayo <i>CALR</i> mutation type classification guide using alpha helix propensity. <i>American Journal of Hematology</i> , 2018, 93, E128-E129. | 4.1 | 18 |
| 98 | Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. <i>Blood Cancer Journal</i> , 2018, 8, 8. | 6.2 | 1 |
| 99 | <i>JAK2</i> exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with <i>JAK2</i> V617F mutated disease. <i>American Journal of Hematology</i> , 2018, 93, E93-E96. | 4.1 | 27 |
| 100 | Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 835-838. | 2.5 | 32 |
| 101 | A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2018, 93, E103-E107. | 4.1 | 1 |
| 102 | Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. <i>British Journal of Haematology</i> , 2018, 182, 437-440. | 2.5 | 22 |
| 103 | A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <i>Leukemia</i> , 2018, 32, 1850-1856. | 7.2 | 25 |
| 104 | Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018, 8, 29. | 6.2 | 49 |
| 105 | Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. <i>British Journal of Haematology</i> , 2018, 182, 594-597. | 2.5 | 31 |
| 106 | Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018, 93, 348-355. | 4.1 | 94 |
| 107 | Screening for <i>ASXL1</i> and <i>SRSF2</i> mutations is imperative for treatment decision-making in otherwise low or intermediate risk patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 678-681. | 2.5 | 19 |
| 108 | Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. <i>American Journal of Hematology</i> , 2018, 93, E61-E64. | 4.1 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318. | 1.6 | 373 |
| 110 | MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 1769-1770. | 1.6 | 249 |
| 111 | MPL-mutated essential thrombocythemia: a morphologic reappraisal. <i>Blood Cancer Journal</i> , 2018, 8, 121. | 6.2 | 17 |
| 112 | Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018, 8, 118. | 6.2 | 7 |
| 113 | Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1500-1537. | 4.9 | 41 |
| 114 | Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018, 94, 363-377. | 4.1 | 133 |
| 115 | Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018, 8, 120. | 6.2 | 1 |
| 116 | A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3-ITD</i> mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404. | 4.1 | 3 |
| 117 | Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 82. | 6.2 | 24 |
| 118 | Mutations and karyotype predict treatment response in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, 1420-1426. | 4.1 | 25 |
| 119 | Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. <i>American Journal of Hematology</i> , 2018, 93, E383-E386. | 4.1 | 2 |
| 120 | Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018, 93, 1474-1484. | 4.1 | 56 |
| 121 | Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018, 2, 370-380. | 5.2 | 90 |
| 122 | Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <i>Blood Advances</i> , 2018, 2, 2964-2972. | 5.2 | 68 |
| 123 | Genotype-phenotype correlation of hereditary erythrocytosis mutations, a single center experience. <i>American Journal of Hematology</i> , 2018, 93, 1029-1041. | 4.1 | 38 |
| 124 | Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018, 8, 57. | 6.2 | 23 |
| 125 | Myelofibrosis Treatment Algorithm 2018. <i>Blood Cancer Journal</i> , 2018, 8, 72. | 6.2 | 31 |
| 126 | A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2018, 150, 421-431. | 0.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. American Journal of Hematology, 2018, 93, E235-E238. | 4.1 | 8 |
| 128 | Mast cell activation syndrome: Importance of consensus criteria and call for research. Journal of Allergy and Clinical Immunology, 2018, 142, 1008-1010. | 2.9 | 27 |
| 129 | CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer Journal, 2018, 8, 21. | 6.2 | 26 |
| 130 | Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. American Journal of Hematology, 2018, 93, 1461-1466. | 4.1 | 24 |
| 131 | How I treat myelofibrosis after failure of JAK inhibitors. Blood, 2018, 132, 492-500. | 1.4 | 40 |
| 132 | Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374. | 3.0 | 20 |
| 133 | Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578. | 1.4 | 5 |
| 134 | 20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. Blood, 2018, 132, 4301-4301. | 1.4 | 1 |
| 135 | 3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035. | 1.4 | 1 |
| 136 | Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040. | 1.4 | 1 |
| 137 | Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. Blood, 2018, 132, 1773-1773. | 1.4 | 3 |
| 138 | Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1821-1821. | 1.4 | 12 |
| 139 | Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. Blood, 2018, 132, 4300-4300. | 1.4 | 0 |
| 140 | Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 2722-2722. | 1.4 | 2 |
| 141 | Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. Blood, 2018, 132, 3034-3034. | 1.4 | 0 |
| 142 | The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. Blood, 2018, 132, 5440-5440. | 1.4 | 1 |
| 143 | The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. Blood, 2018, 132, 1761-1761. | 1.4 | 4 |
| 144 | Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. Blood, 2018, 132, 4287-4287. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. <i>Blood</i> , 2018, 132, 582-582. | 1.4 | 0 |
| 146 | Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018, 132, 1767-1767. | 1.4 | 0 |
| 147 | Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018, 132, 4344-4344. | 1.4 | 0 |
| 148 | Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. <i>Blood</i> , 2018, 132, 3050-3050. | 1.4 | 0 |
| 149 | Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018, 132, 3033-3033. | 1.4 | 0 |
| 150 | Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. <i>Blood</i> , 2018, 132, 4291-4291. | 1.4 | 0 |
| 151 | MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018, 132, 3036-3036. | 1.4 | 0 |
| 152 | Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , 2018, 132, 3100-3100. | 1.4 | 0 |
| 153 | 1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689. | 1.4 | 0 |
| 154 | Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018, 132, 3044-3044. | 1.4 | 0 |
| 155 | A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. <i>Blood</i> , 2018, 132, 1771-1771. | 1.4 | 0 |
| 156 | The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 454-459. | 4.1 | 12 |
| 157 | Monocytosis in polycythemia vera: Clinical and molecular correlates. <i>American Journal of Hematology</i> , 2017, 92, 640-645. | 4.1 | 40 |
| 158 | Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. <i>American Journal of Hematology</i> , 2017, 92, 1311-1317. | 4.1 | 73 |
| 159 | Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627. | 4.1 | 3 |
| 160 | Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. <i>American Journal of Hematology</i> , 2017, 92, 1187-1192. | 4.1 | 21 |
| 161 | Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. <i>American Journal of Hematology</i> , 2017, 92, 1193-1197. | 4.1 | 27 |
| 162 | The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, E5-E6. | 4.1 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. Blood Cancer Journal, 2017, 7, 657. | 6.2 | 13 |
| 164 | Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer Journal, 2017, 7, 658. | 6.2 | 16 |
| 165 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30. | 5.2 | 243 |
| 166 | Next generation sequencing of myeloid neoplasms with eosinophilia harboring the <i>FIP1L1-PDGFR</i> mutation. American Journal of Hematology, 2016, 91, E10-1. | 4.1 | 20 |
| 167 | Systemic mastocytosis: evolving lessons from large patient registry datasets. American Journal of Hematology, 2016, 91, 654-655. | 4.1 | 4 |
| 168 | Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. American Journal of Hematology, 2016, 91, 888-893. | 4.1 | 60 |
| 169 | Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Annals of Hematology, 2016, 95, 1185-1189. | 1.8 | 13 |
| 170 | <i>ASXL1</i> and <i>CBL</i> mutations are independently predictive of inferior survival in advanced systemic mastocytosis. British Journal of Haematology, 2016, 175, 534-536. | 2.5 | 25 |
| 171 | Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American Journal of Hematology, 2016, 91, 503-506. | 4.1 | 47 |
| 172 | Concurrent activating <i>KIT</i> mutations in systemic mastocytosis. British Journal of Haematology, 2016, 173, 153-156. | 2.5 | 12 |
| 173 | Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. American Journal of Hematology, 2016, 91, 1146-1159. | 4.1 | 88 |
| 174 | Targeted next generation sequencing of <i>PDGFRB</i> rearranged myeloid neoplasms with monocytosis. American Journal of Hematology, 2016, 91, E12-4. | 4.1 | 20 |
| 175 | Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. Blood, 2016, 128, 1123-1123. | 1.4 | 4 |
| 176 | Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. Blood, 2016, 128, 2798-2798. | 1.4 | 3 |
| 177 | Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. Blood, 2016, 128, 3113-3113. | 1.4 | 17 |
| 178 | Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. Blood, 2016, 128, 3115-3115. | 1.4 | 1 |
| 179 | Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 4245-4245. | 1.4 | 9 |
| 180 | Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. Blood, 2016, 128, 4247-4247. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. Blood, 2016, 128, 4248-4248. | 1.4 | 1 |
| 182 | Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. Blood, 2016, 128, 4249-4249. | 1.4 | 3 |
| 183 | Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. Blood, 2016, 128, 948-948. | 1.4 | 6 |
| 184 | Initial presentation of CNS-restricted acute lymphoblastic B cell leukaemia as peripheral polyneuropathy. BMJ Case Reports, 2016, 2016, bcr2016214645. | 0.5 | 1 |
| 185 | Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. Blood, 2016, 128, 3129-3129. | 1.4 | 0 |
| 186 | Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. Blood, 2016, 128, 1996-1996. | 1.4 | 0 |
| 187 | Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259. | 1.4 | 0 |
| 188 | Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. Blood, 2016, 128, 1986-1986. | 1.4 | 0 |
| 189 | Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. Blood, 2016, 128, 5534-5534. | 1.4 | 1 |
| 190 | Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. Blood, 2016, 128, 3111-3111. | 1.4 | 1 |
| 191 | The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. Blood, 2016, 128, 3120-3120. | 1.4 | 0 |
| 192 | Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. British Journal of Haematology, 2015, 171, 875-879. | 2.5 | 5 |
| 193 | ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. American Journal of Hematology, 2015, 90, 653-656. | 4.1 | 76 |
| 194 | Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 2015, 21, 1473-1480. | 30.7 | 128 |
| 195 | Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2015, 90, 250-262. | 4.1 | 73 |
| 196 | Myeloproliferative Neoplasms. JAMA Oncology, 2015, 1, 97. | 7.1 | 266 |
| 197 | Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643. | 7.1 | 362 |
| 198 | Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638. | 3.0 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Momelotinib treatmentâ€emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. British Journal of Haematology, 2015, 169, 77-80. | 2.5 | 56 |
| 200 | Morphologically Occult Systemic Mastocytosis in Bone Marrow. American Journal of Clinical Pathology, 2015, 144, 493-502. | 0.7 | 17 |
| 201 | Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. Blood, 2015, 126, 1599-1599. | 1.4 | 1 |
| 202 | Spectrum of Mutations Associated with Hereditary Erythrocytosis. Blood, 2015, 126, 2140-2140. | 1.4 | 2 |
| 203 | Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801. | 1.4 | 1 |
| 204 | Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype. Blood, 2015, 126, 2819-2819. | 1.4 | 1 |
| 205 | A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. Blood, 2015, 126, 350-350. | 1.4 | 1 |
| 206 | Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood, 2015, 126, 354-354. | 1.4 | 14 |
| 207 | Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. Blood, 2015, 126, 4078-4078. | 1.4 | 1 |
| 208 | ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. Blood, 2015, 126, 828-828. | 1.4 | 2 |
| 209 | Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival. Blood, 2015, 126, 1611-1611. | 1.4 | 0 |
| 210 | Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. Blood, 2015, 126, 4062-4062. | 1.4 | 0 |
| 211 | Molecular Correlates of Anemia in Primary Myelofibrosis. Blood, 2015, 126, 4068-4068. | 1.4 | 0 |
| 212 | CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. Blood, 2015, 126, 2802-2802. | 1.4 | 0 |
| 213 | Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875. | 1.4 | 0 |
| 214 | Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. Blood, 2015, 126, 2805-2805. | 1.4 | 9 |
| 215 | ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882. | 1.4 | 2 |
| 216 | Is there a role for JAK inhibitors in<i>BCR-ABL1</i>-negative myeloproliferative neoplasms other than myelofibrosis?. Leukemia and Lymphoma, 2014, 55, 2706-2711. | 1.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | Drug-drug interaction between bosutinib and warfarin. <i>Leukemia and Lymphoma</i> , 2014, 55, 2213-2214. | 1.3 | 3 |
| 218 | CALR mutations and a new diagnostic algorithm for MPN. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 125-126. | 27.6 | 53 |
| 219 | Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. <i>American Journal of Hematology</i> , 2014, 89, E121-4. | 4.1 | 176 |
| 220 | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014, 124, 2507-2513. | 1.4 | 575 |
| 221 | The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. <i>Blood</i> , 2014, 124, 2465-2466. | 1.4 | 135 |
| 222 | In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014, 124, 3021-3023. | 1.4 | 112 |
| 223 | Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 612-624. | 4.1 | 71 |
| 224 | Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398. | 1.4 | 286 |
| 225 | Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. <i>American Journal of Hematology</i> , 2013, 88, 312-316. | 4.1 | 64 |
| 226 | How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 3</i> | 1.4 | 80 |
| 227 | International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401. | 1.4 | 122 |
| 228 | Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 104-104. | 1.4 | 3 |
| 229 | Update On The Long-Term Efficacy and Safety Of Mometinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013, 122, 108-108. | 1.4 | 31 |
| 230 | Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 109-109. | 1.4 | 5 |
| 231 | Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013, 122, 2821-2821. | 1.4 | 1 |
| 232 | Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. <i>Blood</i> , 2013, 122, 2830-2830. | 1.4 | 1 |
| 233 | Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). <i>Blood</i> , 2013, 122, 4047-4047. | 1.4 | 19 |
| 234 | Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Mometinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013, 122, 4049-4049. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood, 2013, 122, 662-662. | 1.4 | 11 |
| 236 | BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. Blood, 2013, 122, 664-664. | 1.4 | 19 |
| 237 | Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587. | 1.4 | 3 |
| 238 | Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis. Blood, 2013, 122, 2824-2824. | 1.4 | 0 |
| 239 | U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. Blood, 2013, 122, 4060-4060. | 1.4 | 0 |
| 240 | Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048. | 1.4 | 0 |
| 241 | Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955. | 1.4 | 0 |
| 242 | Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000. | 1.4 | 0 |
| 243 | One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2012, 87, 25-33. | 3.0 | 181 |
| 244 | Systemic Mastocytosis. Hematology/Oncology Clinics of North America, 2012, 26, 1117-1128. | 2.2 | 19 |
| 245 | Treatment of refractory idiopathic hypereosinophilic syndrome: Pitfalls and progress with use of novel drugs. American Journal of Hematology, 2012, 87, 703-706. | 4.1 | 14 |
| 246 | Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 401-411. | 4.1 | 57 |
| 247 | Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. Blood, 2012, 120, 178-178. | 1.4 | 13 |
| 248 | Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. Blood, 2012, 120, 2836-2836. | 1.4 | 4 |
| 249 | A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. Blood, 2012, 120, 2837-2837. | 1.4 | 10 |
| 250 | Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. Blood, 2012, 120, 2851-2851. | 1.4 | 5 |
| 251 | Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. Blood, 2012, 120, 2867-2867. | 1.4 | 3 |
| 252 | Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. Blood, 2012, 120, 1751-1751. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. Blood, 2012, 120, 1711-1711. | 1.4 | 0 |
| 254 | Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts.. Blood, 2012, 120, 2803-2803. | 1.4 | 0 |
| 255 | Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. Blood, 2012, 120, 3790-3790. | 1.4 | 0 |
| 256 | Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. Blood, 2012, 120, 430-430. | 1.4 | 0 |
| 257 | Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 423-423. | 1.4 | 0 |
| 258 | Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. Blood, 2012, 120, 2831-2831. | 1.4 | 0 |
| 259 | The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. Blood, 2012, 120, 1742-1742. | 1.4 | 9 |
| 260 | Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. Blood, 2012, 120, 2849-2849. | 1.4 | 0 |
| 261 | DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 2011, 29, 392-397. | 1.6 | 854 |
| 262 | Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. Journal of Clinical Oncology, 2011, 29, 1356-1363. | 1.6 | 485 |
| 263 | Neurologic symptoms and diagnosis in adults with mast cell disease. Clinical Neurology and Neurosurgery, 2011, 113, 570-574. | 1.4 | 30 |
| 264 | Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology, 2011, 18, 105-110. | 2.5 | 38 |
| 265 | Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood, 2011, 118, 4595-4598. | 1.4 | 64 |
| 266 | Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770. | 1.6 | 724 |
| 267 | Circulating levels of MCP∑1, sIL−2R, IL−15, and IL−8 predict anemia response to pomalidomide therapy in myelofibrosis. American Journal of Hematology, 2011, 86, 343-345. | 4.1 | 27 |
| 268 | Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2011, 86, 362-371. | 4.1 | 31 |
| 269 | Infrequent occurrence of <i>MPL</i> exon 10 mutations in polycythemia vera and post−polycythemia vera myelofibrosis. American Journal of Hematology, 2011, 86, 701-702. | 4.1 | 29 |
| 270 | Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies. American Journal of Hematology, 2011, 86, 1013-1016. | 4.1 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer, 2011, 117, 4869-4877. | 4.1 | 50 |
| 272 | Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology, 2011, 29, 789-796. | 1.6 | 369 |
| 273 | Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. Blood, 2011, 118, 1759-1759. | 1.4 | 1 |
| 274 | Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood, 2011, 118, 277-277. | 1.4 | 7 |
| 275 | SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,. Blood, 2011, 118, 3838-3838. | 1.4 | 12 |
| 276 | An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. Blood, 2011, 118, 3849-3849. | 1.4 | 16 |
| 277 | Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. Blood, 2011, 118, 3850-3850. | 1.4 | 1 |
| 278 | SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460. | 1.4 | 2 |
| 279 | Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis. , 2011, , 205-221. | | 0 |
| 280 | Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases. Blood, 2011, 118, 2806-2806. | 1.4 | 0 |
| 281 | IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. Blood, 2011, 118, 3795-3795. | 1.4 | 0 |
| 282 | Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 5158-5158. | 1.4 | 0 |
| 283 | Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. Blood, 2011, 118, 1752-1752. | 1.4 | 2 |
| 284 | Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. Blood, 2011, 118, 3833-3833. | 1.4 | 0 |
| 285 | Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 1756-1756. | 1.4 | 1 |
| 286 | Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. Blood, 2011, 118, 971-971. | 1.4 | 0 |
| 287 | Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. Blood, 2011, 118, 5154-5154. | 1.4 | 0 |
| 288 | CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. Blood, 2011, 118, 2807-2807. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 289 | IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. Blood, 2011, 118, 1751-1751. | 1.4 | 5 |
| 290 | Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Current Opinion in Hematology, 2010, 17, 125-132. | 2.5 | 84 |
| 291 | WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood, 2010, 115, 150-151. | 1.4 | 78 |
| 292 | Proposal for a revised classification of systemic mastocytosis. Blood, 2010, 115, 2720-2721. | 1.4 | 17 |
| 293 | Response criteria in systemic mastocytosis: moving forward with practical assessment that reflects meaningful health outcome. European Journal of Haematology, 2010, 85, no-no. | 2.2 | 0 |
| 294 | <i>LNK</i> Mutations in <i>JAK2</i> Mutationâ€“Negative Erythrocytosis. New England Journal of Medicine, 2010, 363, 1189-1190. | 27.0 | 138 |
| 295 | Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New England Journal of Medicine, 2010, 363, 1117-1127. | 27.0 | 1,046 |
| 296 | Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. Blood, 2010, 116, 3068-3068. | 1.4 | 3 |
| 297 | Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. Blood, 2010, 116, 3070-3070. | 1.4 | 7 |
| 298 | LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. Blood, 2010, 116, 4105-4105. | 1.4 | 4 |
| 299 | Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. Blood, 2010, 116, 4112-4112. | 1.4 | 3 |
| 300 | Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden. Blood, 2010, 116, 459-459. | 1.4 | 4 |
| 301 | A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. Blood, 2010, 116, 460-460. | 1.4 | 22 |
| 302 | Epigenomic Profiling of Myeloproliferative Diseases Reveal Idiopathic Myelofibrosis as An Epigenetically Distinct Subgroup and Highlights the Epigenetic Effects of Jak2V617F Mutation. Blood, 2010, 116, 627-627. | 1.4 | 2 |
| 303 | DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. Blood, 2010, 116, 4104-4104. | 1.4 | 1 |
| 304 | Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients. Blood, 2010, 116, 4122-4122. | 1.4 | 0 |
| 305 | A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. Blood, 2010, 116, 4109-4109. | 1.4 | 1 |
| 306 | Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype. Blood, 2010, 116, 3069-3069. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens. Blood, 2010, 116, 4094-4094. | 1.4 | 0 |
| 308 | IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2010, 116, 4009-4009. | 1.4 | 0 |
| 309 | Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon α , hydroxyurea, imatinib mesylate or 2 α -chlorodeoxyadenosine. American Journal of Hematology, 2009, 84, 790-794. | 4.1 | 166 |
| 310 | The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 2009, 33, 1199-1203. | 0.8 | 203 |
| 311 | Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood, 2009, 113, 5727-5736. | 1.4 | 484 |
| 312 | Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood, 2009, 114, 3769-3772. | 1.4 | 157 |
| 313 | IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.. Blood, 2009, 114, 2909-2909. | 1.4 | 9 |
| 314 | Primary eosinophilic disorders: A concise review. Current Hematologic Malignancy Reports, 2008, 3, 37-43. | 2.3 | 8 |
| 315 | JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients. Mayo Clinic Proceedings, 2008, 83, 457-459. | 3.0 | 47 |
| 316 | Phase II Study of Dasatinib in Philadelphia Chromosome α -Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Clinical Cancer Research, 2008, 14, 3906-3915. | 7.0 | 151 |
| 317 | Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood, 2008, 111, 2785-2789. | 1.4 | 135 |
| 318 | Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424. Blood, 2008, 112, 2802-2802. | 1.4 | 12 |
| 319 | The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2. Blood, 2008, 112, 2804-2804. | 1.4 | 12 |
| 320 | TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFRA in Vitro. Blood, 2008, 112, 2807-2807. | 1.4 | 1 |
| 321 | Prognostically Relevant Breakdown of 138 Patients with Systemic Mastocytosis Associated with Another Hematological Malignancy. Blood, 2008, 112, 2808-2808. | 1.4 | 0 |
| 322 | Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer, 2007, 109, 2279-2284. | 4.1 | 149 |
| 323 | Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. British Journal of Haematology, 2007, 138, 354-358. | 2.5 | 139 |
| 324 | Extending JAK2V617F and MPLW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes. Stem Cells, 2007, 25, 2358-2362. | 3.2 | 65 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. Blood, 2007, 110, 3546-3546. | 1.4 | 2 |
| 326 | INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. Blood, 2007, 110, 558-558. | 1.4 | 28 |
| 327 | Systemic Mastocytosis: A Concise Clinical and Laboratory Review. Archives of Pathology and Laboratory Medicine, 2007, 131, 784-791. | 2.5 | 49 |
| 328 | Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level \leq 10 g/dL.. Blood, 2007, 110, 3555-3555. | 1.4 | 0 |
| 329 | Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. Blood, 2007, 110, 676-676. | 1.4 | 2 |
| 330 | Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. Blood, 2007, 110, 2550-2550. | 1.4 | 0 |
| 331 | JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. Blood, 2007, 110, 3191-3191. | 1.4 | 0 |
| 332 | A role for tryptase in myeloid disorders?. Leukemia and Lymphoma, 2006, 47, 789-790. | 1.3 | 1 |
| 333 | Dysregulated EVI1 expression in myeloid malignancies. Leukemia and Lymphoma, 2006, 47, 2443-2444. | 1.3 | 1 |
| 334 | Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood, 2006, 107, 4572-4573. | 1.4 | 30 |
| 335 | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 2006, 108, 3472-3476. | 1.4 | 963 |
| 336 | TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. Blood, 2006, 108, 2680-2680. | 1.4 | 5 |
| 337 | MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. Blood, 2006, 108, 116-116. | 1.4 | 6 |
| 338 | Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. Blood, 2006, 108, 661-661. | 1.4 | 0 |
| 339 | â€™Idiopathicâ€™ Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFR α Status, and Clinical Course.. Blood, 2006, 108, 2701-2701. | 1.4 | 0 |
| 340 | Low Incidence of FIP1L1-PDGFR α in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. Blood, 2005, 106, 2590-2590. | 1.4 | 1 |
| 341 | Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leukemia Research, 2004, 28, 47-52. | 0.8 | 24 |
| 342 | Clinical, genetic, and therapeutic insights into systemic mast cell disease. Current Opinion in Hematology, 2004, 11, 58-64. | 2.5 | 73 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | FIP1L1-PDGFR α fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. <i>Blood</i> , 2004, 104, 3038-3045. | 1.4 | 297 |
| 344 | FIP1L1-PDGFR α and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. <i>Haematologica</i> , 2004, 89, 871-3. | 3.5 | 45 |
| 345 | Chronic basophilic leukemia: a distinct clinico-pathologic entity?. <i>European Journal of Haematology</i> , 2003, 71, 18-22. | 2.2 | 25 |
| 346 | Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. <i>Leukemia Research</i> , 2003, 27, 739-742. | 0.8 | 40 |
| 347 | Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. <i>British Journal of Haematology</i> , 2003, 120, 691-694. | 2.5 | 21 |
| 348 | Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. <i>Leukemia Research</i> , 2003, 27, 883-885. | 0.8 | 79 |
| 349 | 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell Histiocytosis. <i>Mayo Clinic Proceedings</i> , 2003, 78, 301-306. | 3.0 | 75 |
| 350 | Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. <i>Blood</i> , 2003, 101, 827-830. | 1.4 | 69 |
| 351 | Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. <i>Blood</i> , 2003, 101, 3391-3397. | 1.4 | 206 |
| 352 | CHIC2 deletion, a surrogate for FIP1L1-PDGFR α fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. <i>Blood</i> , 2003, 102, 3093-3096. | 1.4 | 368 |
| 353 | Systemic Mast Cell Disease Without Associated Hematologic Disorder: A Combined Retrospective and Prospective Study. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1169-1175. | 3.0 | 38 |
| 354 | Primer on Medical Genomics Part IV: Expression Proteomics. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1185-1196. | 3.0 | 25 |